Actinogen Medical Ltd has released a press release.
XanaMIA Part A trial achieves target enrolment
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Strategic Update & Capital Raising Investor Presentation
- Program Expansion & Capital Raising
- ACW announces open IND for Phase 2 Fragile X trial & LOI
- R&D Tax Incentive Rebate received of A$1.435 million
- Actinogen Medical FY21 Results- Progressing the Pipeline
Later from Actinogen Medical
- ACW Strategic Collaboration with Oxford Uni Researchers
- Capital Raising Completion
- Actinogen Medical: ACW CEO Presents at San Francisco Healthcare Conference
- Actinogen appoints XanaFX Phase 2 trial manager
- Actinogen XanaMIA Part A trial results expected in April
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical